Neogen (NEOG): 40% Undervalued Despite FDA Warning
NEOG stock analysis: 60% earnings beat signals turnaround — full deep dive
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down Neogen Corporation (NEOG) and its operational turnaround driven by a Q1 revenue beat and the $160 million divestiture of its genomics division. With core organic revenue growing 8.1% YoY and Adjusted EBITDA margins expanding to 18.7%, the key question for investors is whether manufacturing…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.